20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kiniksa Pharmaceuticals Ltd (KNSA) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in London, United Kingdom with about 366 employees. Its market capitalization is roughly $6 billion. In the fiscal year ended 2025-12-31, KNSA reported $678M in revenue and $59M in net income.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Interactive charts & full statements → Open the KNSA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $841M | $678M | $423M | $270M | $220M | $39M | $8M | $0M | $0M | $0M | $0M |
| Gross Profit | $458M | $370M | $362M | $214M | $197M | $29M | ($4M) | ($3M) | $0M | $0M | $0M |
| Gross Margin % | 54.5% | 54.6% | 85.6% | 79.1% | 89.6% | 76.4% | -49.4% | — | — | — | — |
| Operating Income (EBIT) | $100M | $77M | ($46M) | ($25M) | $10M | ($157M) | ($157M) | ($170M) | ($108M) | ($65M) | ($24M) |
| Operating Margin % | 11.9% | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | -2042.6% | — | — | — | — |
| Net Income | $80M | $59M | ($43M) | $14M | $183M | ($158M) | ($161M) | ($162M) | ($103M) | ($65M) | ($24M) |
| Net Margin % | 9.5% | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | -2094.8% | — | — | — | — |
| EBITDA | $113M | $90M | ($34M) | ($14M) | $13M | ($154M) | ($155M) | ($168M) | ($108M) | ($65M) | ($24M) |
| Earnings Per Share (EPS) | $0.99 | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | $-3.49 | $-2.00 | $-0.74 |
| Shares Outstanding (M) | 83M | 79M | 71M | 72M | 70M | 69M | 62M | 54M | 30M | 32M | 32M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $244M | $214M | $202M | $181M | $157M | $138M | $123M | $112M |
| Gross Profit | $132M | $118M | $111M | $97M | $86M | $76M | $56M | $63M |
| Gross Margin % | 54.2% | 55.0% | 54.9% | 53.8% | 54.7% | 55.2% | 46.0% | 56.0% |
| Operating Income (EBIT) | $27M | $29M | $20M | $24M | $20M | $13M | ($19M) | ($10M) |
| Operating Margin % | 11.2% | 13.7% | 9.8% | 13.3% | 12.9% | 9.6% | -15.8% | -8.6% |
| Net Income | $25M | $23M | $14M | $18M | $18M | $9M | ($9M) | ($13M) |
| Net Margin % | 10.4% | 10.5% | 7.0% | 10.2% | 11.4% | 6.2% | -7.2% | -11.3% |
| EBITDA | $28M | $33M | $24M | $28M | $23M | $16M | ($17M) | ($7M) |
| Earnings Per Share (EPS) | $0.30 | $0.27 | $0.18 | $0.24 | $0.23 | $0.11 | $-0.12 | $-0.18 |
| Shares Outstanding (M) | 83M | 82M | 79M | 78M | 78M | 76M | 72M | 72M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $185M | $138M | $26M | $13M | $6M | ($126M) | ($137M) | ($158M) | ($81M) | ($50M) | ($22M) |
| Capital Expenditures (CapEx) | $3M | $0M | $0M | $0M | $0M | $20M | $0M | $3M | $5M | $0M | $0M |
| Free Cash Flow (FCF) | $183M | $137M | $25M | $13M | $6M | ($147M) | ($137M) | ($162M) | ($86M) | ($50M) | ($22M) |
| FCF Margin % | 21.8% | 20.2% | 6.0% | 4.9% | 2.6% | -380.6% | -1775.9% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $47M | $50M | $54M | $34M | $28M | $22M | $19M | ($2M) |
| Capital Expenditures (CapEx) | $1M | $0M | $1M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $47M | $50M | $53M | $33M | $28M | $22M | $19M | ($2M) |
| FCF Margin % | 19.2% | 23.4% | 26.4% | 18.2% | 17.8% | 16.1% | 15.2% | -2.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $896M | $764M | $581M | $526M | $460M | $233M | $349M | $255M | $322M | $47M | $56M |
| Cash & Cash Equivalents | $176M | $166M | $184M | $108M | $123M | $122M | $114M | $47M | $307M | $46M | $56M |
| Total Liabilities | $242M | $196M | $142M | $87M | $64M | $48M | $38M | $29M | $43M | $137M | $82M |
| Total Debt (Short + Long-Term) | $4M | $3M | $2M | $2M | $3M | $3M | $2M | $2M | $0M | $0M | $0M |
| Total Shareholders' Equity | $654M | $568M | $438M | $439M | $396M | $185M | $312M | $225M | ($194M) | ($90M) | ($26M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KNSA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms